TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06316297: A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of A

Sponsor: Sanofi Pasteur, a Sanofi Company · Phase: PHASE1/PHASE2 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 800 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$2,916,690

Rescue Site Savings

+$1,929,840

Unlock Full NCT06316297 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06316297 Rescue Dossier →